These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 9884009)
1. Does age influence screening for colorectal cancer? Borum ML Age Ageing; 1998 Jul; 27(4):509-11. PubMed ID: 9884009 [TBL] [Abstract][Full Text] [Related]
2. Medical residents' colorectal cancer screening may be dependent on ambulatory care education. Borum ML Dig Dis Sci; 1997 Jun; 42(6):1176-8. PubMed ID: 9201080 [TBL] [Abstract][Full Text] [Related]
3. A case-control study to evaluate efficacy of screening for faecal occult blood. Lazovich D; Weiss NS; Stevens NG; White E; McKnight B; Wagner EH J Med Screen; 1995; 2(2):84-9. PubMed ID: 7497161 [TBL] [Abstract][Full Text] [Related]
4. Colorectal cancer surveillance in African-American and white patients at an urban university medical center. Borum ML J Natl Med Assoc; 1999 Sep; 91(9):505-8. PubMed ID: 10517070 [TBL] [Abstract][Full Text] [Related]
5. Survey of internal medicine residents' use of the fecal occult blood test and their understanding of colorectal cancer screening and surveillance. Sharma VK; Corder FA; Raufman JP; Sharma P; Fennerty MB; Howden CW Am J Gastroenterol; 2000 Aug; 95(8):2068-73. PubMed ID: 10950059 [TBL] [Abstract][Full Text] [Related]
6. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. Winawer SJ; Flehinger BJ; Schottenfeld D; Miller DG J Natl Cancer Inst; 1993 Aug; 85(16):1311-8. PubMed ID: 8340943 [TBL] [Abstract][Full Text] [Related]
7. Is the type of test used for mass colorectal cancer screening a determinant of compliance? A cluster-randomized controlled trial comparing fecal occult blood testing with flexible sigmoidoscopy. Federici A; Marinacci C; Mangia M; Borgia P; Giorgi Rossi P; Guasticchi G Cancer Detect Prev; 2006; 30(4):347-53. PubMed ID: 16965874 [TBL] [Abstract][Full Text] [Related]
8. Faecal occult blood screening: knowledge, attitudes, and practice in four Hong Kong primary care clinics. Tam TK; Ng KK; Lau CM; Lai TC; Lai WY; Tsang LC Hong Kong Med J; 2011 Oct; 17(5):350-7. PubMed ID: 21979470 [TBL] [Abstract][Full Text] [Related]
9. Colorectal cancer screening by obstetrician-gynecologists. Musinski SE Am J Obstet Gynecol; 2001 May; 184(6):1054-6. PubMed ID: 11349154 [TBL] [Abstract][Full Text] [Related]
10. Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and use of the fecal occult blood test. Sharma VK; Corder FA; Fancher J; Howden CW Am J Gastroenterol; 2000 Dec; 95(12):3629-32. PubMed ID: 11151904 [TBL] [Abstract][Full Text] [Related]
11. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening. Berry DP; Clarke P; Hardcastle JD; Vellacott KD Br J Surg; 1997 Sep; 84(9):1274-6. PubMed ID: 9313712 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the occult blood test in screening for colorectal neoplasms. A prospective study using flexible endoscopy. Reilly JM; Ballantyne GH; Fleming FX; Zucker KA; Modlin IM Am Surg; 1990 Mar; 56(3):119-23. PubMed ID: 2316930 [TBL] [Abstract][Full Text] [Related]
13. Screening for colorectal cancer using the faecal occult blood test, hemoccult. Towler BP; Irwig L; Glasziou P; Weller D; Kewenter J Cochrane Database Syst Rev; 2000; (2):CD001216. PubMed ID: 10796760 [TBL] [Abstract][Full Text] [Related]
14. Determinants of participation in colorectal cancer screening with faecal occult blood testing. von Euler-Chelpin M; Brasso K; Lynge E J Public Health (Oxf); 2010 Sep; 32(3):395-405. PubMed ID: 20015868 [TBL] [Abstract][Full Text] [Related]
15. Validity of immunological faecal occult blood screening for colorectal cancer: a follow up study. Nakama H; Kamijo N; Abdul Fattah AS; Zhang B J Med Screen; 1996; 3(2):63-5. PubMed ID: 8849761 [TBL] [Abstract][Full Text] [Related]
16. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. Weissfeld JL; Schoen RE; Pinsky PF; Bresalier RS; Church T; Yurgalevitch S; Austin JH; Prorok PC; Gohagan JK; J Natl Cancer Inst; 2005 Jul; 97(13):989-97. PubMed ID: 15998952 [TBL] [Abstract][Full Text] [Related]
17. Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based faecal occult blood testing: a French population-based controlled study (Wintzenheim trial). Denis B; Gendre I; Aman F; Ribstein F; Maurin P; Perrin P Eur J Cancer; 2009 Dec; 45(18):3282-90. PubMed ID: 19665368 [TBL] [Abstract][Full Text] [Related]
18. Immunological faecal occult blood testing: a discriminatory test to identify colorectal cancer in symptomatic patients. Kaul A; Shah A; Magill FH; Hawkins SA; Skaife P Int J Surg; 2013; 11(4):329-31. PubMed ID: 23459187 [TBL] [Abstract][Full Text] [Related]
19. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594 [TBL] [Abstract][Full Text] [Related]
20. Colorectal cancer screening: yield of faecal occult blood testing. Teoh ML; Puvan R; Cheah PY; Yuen Y Asian Pac J Cancer Prev; 2010; 11(1):153-6. PubMed ID: 20593948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]